| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $18.8M | +72.1% |
| R&D Expense | $559.2M | +84.2% |
| SG&A Expense | $205.5M | +138.3% |
| Operating Income | -$745.9M | -96.9% |
| Pre-tax Income | -$684.6M | -112.4% |
| Income Tax | $0 | — |
| Net Income | -$684.6M | -112.4% |
| EPS (Basic) | -$4.97 | -72.0% |
| EPS (Diluted) | -$4.97 | -72.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $382.5M | +74.0% |
| Current Assets | $1.80B | +16.6% |
| Total Assets | $1.96B | +25.2% |
| Current Liabilities | $195.4M | +99.4% |
| Total Liabilities | $269.4M | +93.9% |
| Stockholders' Equity | $1.69B | +18.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$650.4M | -116.2% |
| Capital Expenditures | $13.3M | +88.5% |
| Investing Cash Flow | -$38.0M | +95.5% |
| Financing Cash Flow | $851.0M | -28.6% |
| Free Cash Flow | -$663.8M | -115.6% |